Navigation Links
Wistar Institute researcher receives 'New Innovator' award from NIH
Date:9/22/2008

A Wistar Institute researcher's novel approach to understanding genetic causes of human disease has earned him an NIH Director's New Innovator Award and grant from the National Institutes of Health.

Ken-ichi Noma, Ph.D., an assistant professor in Wistar's Gene Expression and Regulation Program, is working to develop a new method of mapping the three-dimensional structure of the human genome. These efforts aim to identify the molecular basis for many diseases, including cancers, and may aid in the development of new diagnostic tests and treatments.

New Innovator Awards support exceptionally creative scientists who take highly innovative and often unconventional approaches to major challenges in biomedical or behavioral research. Winners receive a grant of $1.5 million over five years to support their work. Only early-career investigators who have not yet received a major NIH grant are eligible. Noma is one of 31 researchers worldwide who received the grants this year.

"It's an honor to receive this award, which is a vote of confidence in my idea," Noma says. "The grant will allow me to pursue this line of research, which could have a huge impact. This work has the potential to elucidate an extremely important but poorly understood aspect of human disease."

The human genome exists in the cell nucleus as a complex, three-dimensional entity, the structure of which is disorganized in certain diseases, including cancers. However, it is unclear how the organization of the genome influences disease development. One impediment to understanding that process is an inability to accurately measure, in any given cell, the three-dimensional structure of the chromosomes that contain DNA. Noma proposes to develop a novel system for decoding that structure. Doing so could shed light on the molecular basis of numerous human diseases.

"Original, inventive ideas are what drive Wistar's lifesaving advances in biomedical research," notes Wistar President and CEO Russel E. Kaufman, M.D. "Dr. Noma exemplifies the energy and creativity that will lead to new solutions to today's major medical challenges.

His innovative approach to defining the structure of the human genome holds great potential for helping us understand the genetic basis of cancer and many other diseases."

Noma's work as a scientist has been marked by ingenuity. As a graduate student in the bioengineering department at Nagaoka University in Japan, he developed a strain of carrot that could grow in the desert. While a postdoctoral fellow in the lab of geneticist Shiv Grewal, Ph.D., at Cold Spring Harbor Laboratory, he mapped an uncharted region of the fission yeast genome and published the results in Science a notable feat for a fledgling researcher. He went on to further elucidate genome dynamics in fission yeast as a staff scientist at the National Cancer Institute's Laboratory of Biochemistry and Molecular Biology, where he worked prior to joining Wistar in September 2007. Noma's extensive research on yeast informs his current work with the human genome.

In announcing the New Innovator Awards, NIH Director Elias A. Zerhouni, M.D., said, "Nothing is more important to me than stimulating and sustaining deep innovation, especially for early career investigators and despite challenging budgetary times. These highly creative researchers are tackling important scientific challenges with bold ideas and inventive technologies that promise to break through barriers and radically shift our understanding."


'/>"/>

Contact: Abbey J. Porter
aporter@wistar.org
215-898-3790
The Wistar Institute
Source:Eurekalert

Related biology news :

1. Swiss Institute of Bioinformatics 10th Anniversary Conference
2. Syracuse University partners with Serum Institute of India to develop vaccines for children
3. Cornell gets $10 million NSF grant to establish new sustainability institute
4. Eli and Edythe L. Broad make unprecedented gift to endow Broad Institute of Harvard & MIT
5. NYU Cancer Institute researcher among first NIH EUREKA award recipients
6. Broad Institute awarded grant to develop chemical probes for human biology and disease
7. Broad Institute researchers introduce next generation tool for visualizing genomic data
8. Baker Institute report proposes strategies to ensure global energy security
9. New study spotlights National Institutes of Health grant outcomes for clinical research
10. UC San Diego launches Institute of Engineering in Medicine to accelerate health care tech
11. New round of Environmental Venture Projects from Stanfords Woods Institute
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2017)... Research and Markets has announced the addition ... and Commercial Aspects" to their offering. ... Biomarkers play an ... for selection of treatment as well for monitoring the results. ... in modern medicine. Biochip/microarray technologies and next generation sequencing are ...
(Date:2/8/2017)... NEW YORK , Feb. 7, 2017 Report ... ... and should reach $11.4 billion by 2021, growing at a ... Report Includes - An overview of the global markets for ... from 2015, estimates for 2016, and projections of compound annual ...
(Date:2/7/2017)... Feb. 7, 2017 Zimmer Biomet Holdings, Inc. ... healthcare, will present at the LEERINK Partners 6th Annual ... Hotel on Wednesday, February 15, 2017 at 10 a.m. ... the presentation can be accessed at http://wsw.com/webcast/leerink28/zbh .  ... conference via Zimmer Biomet,s Investor Relations website at ...
Breaking Biology News(10 mins):
(Date:2/16/2017)... 2017   Capricor Therapeutics, Inc. (NASDAQ: ... developing first-in-class biological therapies for cardiac and other ... to terminate its license agreement with the Mayo ... Cenderitide. "Our decision to return these ... our efforts to advance our core cell and ...
(Date:2/16/2017)... , Feb. 16, 2017  Champions Oncology, Inc. ... the development and sale of advanced technology solutions and ... drugs, today announced the addition of new cohorts of ... These new models will expand Champions, product line in ... and neck cancer, AML, and non-small cell lung cancer ...
(Date:2/16/2017)... WEST LAFAYETTE, Indiana (PRWEB) , ... ... ... a division of Albany Molecular Research Inc. has further extended its industry ... sector. This service offers state-of-the-art cGMP techniques and methods for the ...
(Date:2/15/2017)... Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), today announced financial ... full year ended December 31, 2016. ... we continued to demonstrate strong growth in our ... said Mihael H. Polymeropoulos, M.D., Vanda,s President and ... 2017 milestones underscores Vanda,s commitment to bringing important ...
Breaking Biology Technology: